Pharma: Page 16
-
Getty Images
Sanofi finds a silver lining in mixed MS drug results
Tolebrutinib, which Sanofi acquired in a $3.7 billion deal, failed two studies in people with relapsing disease, but succeeded in a type of multiple sclerosis that has no approved therapies.
By Ben Fidler • Sept. 3, 2024 -
Getty Images Signature via Canva.com
Sponsored by StoryfulScript for success: The value of digital insights in pharma
Pharma companies can thrive in 2024 by leveraging digital intelligence to anticipate trends, analyze sentiment, and engage audiences. Discover how data-driven insights drive success.
Sept. 3, 2024 -
Explore the Trendline➔
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
TrendlineAlzheimer's disease
Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.
By BioPharma Dive staff -
Getty Images
Novo builds heart failure case for semaglutide; Ventyx CFO departs
A new analysis showed semaglutide reduced the risk of worsening heart failure. Elsewhere, the FDA OK’d a vaccine for mpox and a biotech planned layoffs.
By BioPharma Dive staff • Aug. 30, 2024 -
Kena Betancur via Getty Images
Keytruda fails lung and skin cancer trials, limiting further expansion
The trial setbacks for Merck’s best-selling drug, which faces patent expiration in 2028, are a blow to the company’s plans for further indication expansion.
By Jonathan Gardner • Aug. 29, 2024 -
Mario Tama via Getty Images
J&J submits touted autoimmune disease drug for FDA approval
Nipocalimab is one of several drugs J&J has forecast for multi-billion dollar sales. The company’s initial application is for its use in myasthenia gravis.
By Kristin Jensen • Aug. 29, 2024 -
Jeenah Moon via Getty Images
Pfizer launches DTC service for migraine, COVID drugs
The platform is similar in concept to a service launched this year by Eli Lilly, and aims to give consumers easier access to Pfizer’s migraine, COVID-19 and flu treatments.
By Delilah Alvarado • Aug. 27, 2024 -
Getty Images
Lilly rolls out Zepbound vials at a discount price
The launch of a single-use vial form of the popular weight loss medicine could help Lilly improve supply and compete with telehealth companies offering compounded versions.
By Ned Pagliarulo • Aug. 27, 2024 -
Getty Images
RA Capital-backed startup raises $100M; UCB sells China business
New biotech Navigator is working on drugs for immune diseases. Meanwhile, UCB sold its neurology and allergy business in China, and J&J's Peter Fasolo will retire this year.
By BioPharma Dive staff • Aug. 27, 2024 -
Courtesy of Regeneron Pharmaceuticals
Regeneron gains European approval for bispecific lymphoma drug
Regulators in Europe granted approval based on remission rates, while the FDA sought more progress in confirmatory trials when it rejected Ordspono.
By Jonathan Gardner • Aug. 26, 2024 -
Getty Images
FDA to convene immunotherapy panel; Tome scales back operations
Agency advisers will discuss whether use of Keytruda and Opdivo should be limited in gastric cancer. Elsewhere, a buzzy genetic drug startup is exploring “strategic options.”
By BioPharma Dive staff • Aug. 23, 2024 -
Courtesy of Regeneron Pharmaceuticals
Regeneron confirms FDA won’t approve myeloma drug over manufacturing issues
Company executives had warned investors that a delay was likely due to issues at a facility run by a third-party manufacturer.
By Kristin Jensen • Aug. 21, 2024 -
Getty Images
Lilly’s tirzepatide cuts diabetes risk, study data show
Treatment with the GLP-1 drug, which Lilly sells as Mounjaro and Zepbound, lowered the risk of Type 2 diabetes progression by 94% versus placebo.
By Ned Pagliarulo • Aug. 20, 2024 -
Getty Images
As Bristol Myers’ schizophrenia drug nears approval, AbbVie and others hope to provide competition
A new wave of antipsychotics could improve patient adherence. The race to corner this large projected market is already getting tight.
By Kelly Bilodeau • Aug. 19, 2024 -
Jeenah Moon via Getty Images
Pfizer, BioNTech stumble in effort to develop combination flu, COVID shot
The vaccine didn’t spur a strong enough immune response against a particular flu strain in a Phase 3 trial, leading the companies to ponder adjustments.
By Delilah Alvarado • Aug. 16, 2024 -
Getty Images
Lilly opens R&D hub; Ovid and Lexicon lay off staff
Lilly’s new center in Boston will focus on genetic medicine research and provide lab space for startups. Elsewhere, two biotechs cut jobs and two others advanced psychedelic medicines.
By BioPharma Dive staff • Aug. 13, 2024 -
Courtesy of Merck & Co.
Immune resetMerck bets $700M on an antibody drug’s potential in immune diseases
The deal hands Merck a cancer medicine already in human testing, but that the company sees as a potential treatment for autoimmune conditions, too.
By Ben Fidler • Aug. 9, 2024 -
Getty Images
Merck TIGIT drug fails another trial; Intellia therapy succeeds in HAE study
Merck stopped a Phase 3 TIGIT study for futility. Elsewhere, shares in Cabaletta Bio sank on safety worries and Vertex secured Casgevy reimbursement in England.
By BioPharma Dive staff • Aug. 8, 2024 -
Getty Images
Zepbound shortages ease, but Lilly cautions pharmacy availability may remain ‘choppy’
After months of supply strains, Lilly has begun to catch up with demand. Consumers may still need to wait for their prescriptions to be filled, however.
By Delilah Alvarado • Aug. 8, 2024 -
Scott Olson via Getty Images
Lilly boosts outlook on rising Zepbound revenue
Sales of the in-demand obesity drug crested $1 billion in the second quarter as improved Lilly production helped the company fulfill wholesaler backorders.
By Ned Pagliarulo • Aug. 8, 2024 -
Getty Images
Amgen talks obesity drug ‘differentiation’; Servier brain cancer drug approved by FDA
Executives at Amgen had few updates on their drug MariTide, but defended what they see as the once-monthly shot’s competitive profile.
By BioPharma Dive staff • Aug. 7, 2024 -
Courtesy of Novo Nordisk
Novo shares tumble on lower-than-expected obesity drug sales
Quarterly revenue from Ozempic and Wegovy missed Wall Street estimates by about 9%, concerning some analysts and causing a stock sell-off costing the Danish drugmaker tens of billions in market value.
By Kristin Jensen • Aug. 7, 2024 -
Getty Images
Zepbound, Mounjaro back in supply as Lilly resolves shortage
All doses of the in-demand GLP-1 medicines are now available in the U.S., Lilly said ahead of reporting second quarter earnings later this week.
By Ned Pagliarulo • Aug. 5, 2024 -
Courtesy of BMS
Bristol Myers sends TIGIT drug back to Agenus
The decision makes Bristol the latest pharma to pull back on research into a type of cancer immunotherapy that’s drawn significant investment in recent years.
By Ben Fidler • Aug. 5, 2024 -
Adobe Stock / MP Studio
Sponsored by MMITWhy pharma should invest in evidence-based physician education
For years, many manufacturers have assumed that pre-market physician education was not strictly necessary unless their brand was the first to market or had a novel mechanism of action. With the advent of precision medicine, however, ongoing disease state education has become increasingly critical...
By Dr. Shrinal Patel and Carolyn Zele • Aug. 5, 2024 -
Getty Images
Vir retreats from infectious disease; Vertex shelves AATD drugs
The one-time drug developer is pivoting to cancer research. Elsewhere, Neurocrine reported a strong quarter and venBio raised half a billion dollars for biotech investing.
By BioPharma Dive staff • Aug. 2, 2024
Previous
